152 related articles for article (PubMed ID: 38277541)
61. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
[TBL] [Abstract][Full Text] [Related]
62. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
63. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
64. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
65. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
66. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.
Chen W; Shu K; Cai C; Ding J; Zhang X; Zhang W; Wang K
Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37584192
[TBL] [Abstract][Full Text] [Related]
67. Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer.
Zhou M; Lv S; Hou Y; Zhang R; Wang W; Yan Z; Li T; Gan W; Zeng Z; Zhang F; Yang M
Front Immunol; 2022; 13():994874. PubMed ID: 36330513
[TBL] [Abstract][Full Text] [Related]
68. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
69. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma.
Xue W; Qiu K; Dong B; Guo D; Fu J; Zhu C; Niu Z
Cancer Cell Int; 2023 Sep; 23(1):218. PubMed ID: 37759294
[TBL] [Abstract][Full Text] [Related]
70. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
71. Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma.
Fu Y; Si A; Wei X; Lin X; Ma Y; Qiu H; Guo Z; Pan Y; Zhang Y; Kong X; Li S; Shi Y; Wu H
BMC Genomics; 2023 Feb; 24(1):89. PubMed ID: 36849926
[TBL] [Abstract][Full Text] [Related]
72. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma.
Chen S; Liu P; Zhao L; Han P; Liu J; Yang H; Li J
Front Immunol; 2022; 13():954653. PubMed ID: 36189204
[TBL] [Abstract][Full Text] [Related]
73. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
74. Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer.
Cai J; Ji Z; Wu J; Chen L; Zheng D; Chen Y; Zhang X; Xie W; Huang J; Chen M; Lin R; Lin W; Chen Y; Li Z
Front Genet; 2022; 13():949314. PubMed ID: 36092873
[TBL] [Abstract][Full Text] [Related]
75. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
76. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
77. Identification of an immune-related 6-lncRNA panel with a good performance for prognostic prediction in hepatocellular carcinoma by integrated bioinformatics analysis.
Lu S; Liu X; Wu C; Zhang J; Stalin A; Huang Z; Tan Y; Wu Z; You L; Ye P; Fu C; Zhang X; Wu J
Medicine (Baltimore); 2023 Jul; 102(29):e33990. PubMed ID: 37478241
[TBL] [Abstract][Full Text] [Related]
78. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
79. Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma.
Huang DP; Liao MM; Tong JJ; Yuan WQ; Peng DT; Lai JP; Zeng YH; Qiu YJ; Tong GD
Aging (Albany NY); 2021 Nov; 13(22):24621-24639. PubMed ID: 34799469
[TBL] [Abstract][Full Text] [Related]
80. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.
Zhang Q; Huang Y; Xia Y; Liu Y; Gan J
Clin Exp Med; 2023 Oct; 23(6):2051-2064. PubMed ID: 36153416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
